Myriad Genetics and SOPHiA GENETICS Announce New Collaboration to Advance Prostate Genomic Instability Score Technology
Key Highlights
- ➤Myriad and SOPHiA GENETICS announce collaboration with AstraZeneca on prostate PrGIS technology
- ➤MyChoice CDx will produce PrGIS scores and advance toward a prostate cancer indication
- ➤SOPHiA GENETICS is developing a decentralized companion diagnostic solution incorporating PrGIS
- ➤SOPHiA GENETICS platform connects more than 1,000 institutions across over 75 countries
- ➤Myriad plans to present co-authored PrGIS research with AstraZeneca at ESMO Congress 2026
Expert Statements
Lou Welebob, Senior Vice President, Companion Diagnostics, Myriad Genetics
“This collaboration showcases Myriad’s biopharma capabilities to support development of precision oncology treatments.”
Lou Welebob, Senior Vice President, Companion Diagnostics, Myriad Genetics
“PrGIS is designed to provide biopharma partners with a platform that may support patient stratification in clinical trials and help accelerate companion diagnostic development for precision oncology therapies.”
Jess Lambe, VP & Managing Director of BioPharma Business Development, SOPHiA GENETICS
“Precision medicine has a geographic problem because breakthrough therapies developed in major markets often remain inaccessible to patients in the rest of the world.”
Jess Lambe, VP & Managing Director of BioPharma Business Development, SOPHiA GENETICS
“By pairing Myriad’s world-class biomarker innovation with SOPHiA GENETICS’ global network, we are working toward a solution for this. Together, we’re building a new model for companion diagnostic deployment that could help innovative therapies reach the right patients locally, expanding access to care where it matters the most.”
SALT LAKE CITY and BOSTON, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine and SOPHiA GENETICS (NASDAQ: SOPH) today announce a collaboration to advance new prostate cancer-specific genomic instability score (PrGIS) technology to support precision oncology approaches with AstraZeneca (LSE/STO/NYSE: AZN). PrGIS is a novel biomarker signature designed to assess chromosomal instability associated with homologous recombination deficiency (HRD) in prostate cancer patients. The collaboration aims to advance PrGIS in clinical trials and expand access to precision oncology medicines through potential companion diagnostic solutions.
Myriad developed PrGIS to support HRD as an actionable biomarker in prostate cancer, where HRD is emerging as an important prognostic and predictive biomarker. The proprietary MyChoice® CDx test which is currently available as a companion diagnostic in ovarian cancer, will produce the PrGIS score and is being advanced for prostate cancer as a new indication.
Get started
Create a free account to read the full story.